Title

Clinical Trials

A key aim of the Department of Oncology is the optimal translation of fundamental research into patient benefit and for Oxford to become the leading centre for translational early-phase oncology trials in the UK. Under the direction of its Clinical Director, Professor Mark Middleton, the Department works closely with colleagues in the state-of-the-art NHS Oxford Cancer and Haematology Centre to ensure that opportunities for collaborative research are maximised and that research is rapidly and efficiently translated into cutting-edge clinical treatment for cancer patients.

Please note that as a scientific research department, we are not able to answer questions about cancer care or cancer treatment, and strongly recommend that you contact Cancer Research UK for help with these questions.

Read more about clinical trials in the Department of Oncology.

Prospective

Chief Investigator:
ATR inhibitor and radiotherapy in oesophageal cancer
 
Chief Investigator:
Dr Simon Lord
A single arm exploratory study examining the feasibility of imaging glioblastoma pH using CEST MRI
 

Active

Chief Investigator:
Rebecca Muirhead
Anal squamous cell carcinoma: Investigation of functional imaging during Chemoradiotherapy (CRT)
 
Chief Investigator:
Atovaquone as Tumour hypOxia Modifier
 
Chief Investigator:
A phase I dose escalation study of the PI3K inhibitor BKM120, given concomitantly with palliative radiotherapy for the treatment of Non-Small Cell Lung Cancer (NSCLC).
 
A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia
 
Chief Investigator:
Anne Thomas
A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma
 
Chief Investigator:
An open-labelled study to characterise Fluciclovine (18F) uptake measured by positron emission tomography in breast cancer
 
Chief Investigator:
 
Chief Investigator:
A Sequential Phase I study of MEK 1/2 inhibitors PD-0325901 or Binimetinib combined with cMET inhibitor PF-02341066 in Patients with RAS Mutant and RAS Wild Type (with aberrant c-MET) Colorectal Cancer
 
Chief Investigator:
A two-part, Phase 1 open label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.
 
Chief Investigator:
Dr Shibani Nicum
Randomised Phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with BRCA mutated platinum–resistant ovarian cancer
 
Chief Investigator:
Ahmed Ahmed
A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy
 
Chief Investigator:
A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
 
Chief Investigator:
Andrew Protheroe
A parallel group, open label, multi-centre, randomised, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab. The main study will be preceded by a single-institution safety run-in with intra-patient dose escalation of intravesical pembrolizumab performed in paired patient cohorts to confirm the safety and tolerability of intravesical pembrolizumab and the dose to be used in the randomised phase.
 
Chief Investigator:
Dr Somnath Mukherjee
Systemic therapy and Chemoradiation in Advanced LOcalised Pancreatic cancer – 2
 
Chief Investigator:
Stereotactic Body Radiotherapy (SBRT) pre-operatively for borderline resectable pancreatic cancer.
 
Chief Investigator:
Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised phase III trial.
 

In Follow-up

Chief Investigator:
A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma.
 
Chief Investigator:
Tim Iveson
Short Course Oncology Treatment - A study of adjuvant chemotherapy in colorectal cancer by the CACTUS and OCTO groups.
 

Closed

Chief Investigator:
Shibani Nicum
A Phase II Clinical trial in patients with known BRCA Defective Tumours
 
Chief Investigator:
Janusz Jankowski
A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.
 
Chief Investigator:
Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome
 
Chief Investigator:
David Ferry
Randomised phase III trial of gefitinib 500mg once daily versus placebo in oesophageal cancer progressing after chemotherapy.
 
Chief Investigator:
Andrew Weaver
Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring: A Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients with Metastatic Colorectal or Metastatic Breast Cancer
 
Chief Investigator:
Robin Kennedy
Conventional versus laparoscopic surgery for colorectal cancer within an enhanced programme.
 
Chief Investigator:
Ricky Sharma and Harpreet Wasan
An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.
 
Chief Investigator:
Bass Hassan
 
Chief Investigator:
Bass Hassan
 
Using GPRS mobile phone technology for managing symptoms associated with chemotherapy for colon cancer (The Mobile Phone Project)
 
Chief Investigator:
David Kerr
A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer.
 
Chief Investigator:
A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases
 
Chief Investigator:
RHYTHM-I: modulation of Radiotherapy according to HYpoxia: exploiting changes in the Tumour Microenvironment to improve outcome in rectal cancer
 
A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer.
 
Chief Investigator:
A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours
 
Chief Investigator:
David Kerr
 
About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
Research
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.